Allergy Therapeutics (AGY) - Total Liabilities
Based on the latest financial reports, Allergy Therapeutics (AGY) has total liabilities worth GBX95.74 Million GBX (≈ $11.65K USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Allergy Therapeutics operating cash flow efficiency to assess how effectively this company generates cash.
Allergy Therapeutics - Total Liabilities Trend (2002–2025)
This chart illustrates how Allergy Therapeutics's total liabilities have evolved over time, based on quarterly financial data. Check Allergy Therapeutics asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Allergy Therapeutics Competitors by Total Liabilities
The table below lists competitors of Allergy Therapeutics ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Premier Products Public Company Limited
BK:PPP
|
Thailand | ฿395.74 Million |
|
Anoto Group AB
ST:ANOT
|
Sweden | Skr89.61 Million |
|
BPH Energy Ltd
AU:BPH
|
Australia | AU$786.23K |
|
TME Pharma N.V.
PA:ALTME
|
France | €2.86 Million |
|
Iron Road Ltd
AU:IRD
|
Australia | AU$503.59K |
|
Kiora Pharmaceuticals Inc
NASDAQ:KPRX
|
USA | $7.45 Million |
|
Martina Berto Tbk
JK:MBTO
|
Indonesia | Rp304.65 Billion |
|
Finansa Public Company Limited
BK:FNS
|
Thailand | ฿1.72 Billion |
Liability Composition Analysis (2002–2025)
This chart breaks down Allergy Therapeutics's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see AGY company net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.28 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -3.40 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.42 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Allergy Therapeutics's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Allergy Therapeutics (2002–2025)
The table below shows the annual total liabilities of Allergy Therapeutics from 2002 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | GBX95.74 Million ≈ $11.65K |
+56.64% |
| 2024-06-30 | GBX61.12 Million ≈ $7.44K |
-5.54% |
| 2023-06-30 | GBX64.70 Million ≈ $7.87K |
+83.90% |
| 2022-06-30 | GBX35.18 Million ≈ $4.28K |
-11.05% |
| 2021-06-30 | GBX39.55 Million ≈ $4.81K |
-6.80% |
| 2020-06-30 | GBX42.44 Million ≈ $5.16K |
+37.18% |
| 2019-06-30 | GBX30.94 Million ≈ $3.76K |
+10.57% |
| 2018-06-30 | GBX27.98 Million ≈ $3.40K |
+2.81% |
| 2017-06-30 | GBX27.22 Million ≈ $3.31K |
+3.27% |
| 2016-06-30 | GBX26.36 Million ≈ $3.21K |
+62.38% |
| 2015-06-30 | GBX16.23 Million ≈ $1.97K |
+21.82% |
| 2014-06-30 | GBX13.32 Million ≈ $1.62K |
-6.79% |
| 2013-06-30 | GBX14.29 Million ≈ $1.74K |
+8.59% |
| 2012-06-30 | GBX13.16 Million ≈ $1.60K |
-53.79% |
| 2011-06-30 | GBX28.48 Million ≈ $3.47K |
+12.89% |
| 2010-06-30 | GBX25.23 Million ≈ $3.07K |
-44.25% |
| 2009-06-30 | GBX45.25 Million ≈ $5.51K |
+31.27% |
| 2008-06-30 | GBX34.47 Million ≈ $4.19K |
+123.88% |
| 2007-06-30 | GBX15.40 Million ≈ $1.87K |
+197.37% |
| 2006-06-30 | GBX5.18 Million ≈ $630.01 |
-21.26% |
| 2005-06-30 | GBX6.58 Million ≈ $800.11 |
+58.15% |
| 2004-06-30 | GBX4.16 Million ≈ $505.91 |
-25.78% |
| 2003-06-30 | GBX5.60 Million ≈ $681.60 |
-60.20% |
| 2002-06-30 | GBX14.07 Million ≈ $1.71K |
-- |
About Allergy Therapeutics
Allergy Therapeutics plc, a commercial biotechnology company, focuses on the diagnosis and treatment of allergic disorders in Germany, Austria, United Kingdom, Netherlands, Switzerland, Italy, Spain, and internationally. The company sells injectable and sublingual allergen-specific immunotherapies, and offers treatment of pollen-related allergies, particularly to grasses, weeds, and trees, as wel… Read more